Natco Pharma stock in focus after USFDA issues inspection report
Natco Pharma said it has now received the EIR from the US regulator, communicating the VAI classification.

- Nov 20, 2026,
- Updated Nov 20, 2026 8:59 AM IST
Natco Pharma Ltd shares are in focus on Friday after the company received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Finished Dosage Formulations (FDF) manufacturing unit in Visakhapatnam, Andhra Pradesh. The FDA classified the inspection as Voluntary Action Indicated (VAI).
The USFDA had inspected the facility in Parawada, Visakhapatnam, from August 17 to August 21, 2026. Following the inspection, the company received four observations through Form 483. Natco Pharma said it has now received the EIR from the US regulator, communicating the VAI classification. The company disclosed the development in an exchange filing dated November 20, referring to its earlier intimation on August 21.
Natco Pharma shares closed at Rs 821.50 on Thursday, up Rs 1.10 or 0.13% from the previous close of Rs 820.40. During the session, the stock opened at Rs 821.95, touched a high of Rs 824.40 and a low of Rs 802.85.
The VAI classification indicates that the FDA has identified conditions requiring voluntary corrective action by the company. The inspection report follows the four observations recorded by the regulator during its August inspection. Natco Pharma's latest disclosure confirms receipt of the EIR and the classification communicated by the US FDA.
The company submitted the information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the information of stock exchanges and investors.
Natco Pharma Ltd shares are in focus on Friday after the company received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Finished Dosage Formulations (FDF) manufacturing unit in Visakhapatnam, Andhra Pradesh. The FDA classified the inspection as Voluntary Action Indicated (VAI).
The USFDA had inspected the facility in Parawada, Visakhapatnam, from August 17 to August 21, 2026. Following the inspection, the company received four observations through Form 483. Natco Pharma said it has now received the EIR from the US regulator, communicating the VAI classification. The company disclosed the development in an exchange filing dated November 20, referring to its earlier intimation on August 21.
Natco Pharma shares closed at Rs 821.50 on Thursday, up Rs 1.10 or 0.13% from the previous close of Rs 820.40. During the session, the stock opened at Rs 821.95, touched a high of Rs 824.40 and a low of Rs 802.85.
The VAI classification indicates that the FDA has identified conditions requiring voluntary corrective action by the company. The inspection report follows the four observations recorded by the regulator during its August inspection. Natco Pharma's latest disclosure confirms receipt of the EIR and the classification communicated by the US FDA.
The company submitted the information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the information of stock exchanges and investors.